Article abstract


Nature Medicine 14, 28 - 36 (2008)
Published online: 6 January 2008 | doi:10.1038/nm1699

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

Ronald J Buckanovich1,2,7,8, Andrea Facciabene1,8, Sarah Kim1, Fabian Benencia1,3, Dimitra Sasaroli1,4, Klara Balint1, Dionysios Katsaros6, Anne O'Brien-Jenkins1, Phyllis A Gimotty1,5 & George Coukos1,3


In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ETBR) was associated with the absence of TILs and short patient survival time. The ETBR inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ETBR neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans.

Top
  1. Center for Research on Ovarian Cancer Early Detection and Cure, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  3. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  4. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  5. Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis 68100, Greece.
  6. Department of Obstetrics and Gynecology, University of Turin, Torino 10126, Italy.
  7. Current address: Department of Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.
  8. These authors contributed equally to this work.

Correspondence to: George Coukos1,3 e-mail: gcks@mail.med.upenn.edu



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Opening the gateway to tumors

Nature Medicine News and Views (01 Jan 2008)


Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT